Using multi-modal genetic sequencing techniques, the two former initiatives defined genomic alterations in specific GBM sub-types including IDH1/2, ATRX, and p53 mutations particularly enriched in younger patients with more favorable outcomes. Here, IDH1 is linked to glioblastoma.